Chiara Mugnaini obtained her degree in Biological Sciences with a specialization in physio-pathology at the University of Siena. She worked for three years as Junior Scientist in the Technology-Development Drug Substances (Chiron Vaccines, Siena) performing process analysis and ELISA/Bactericidal assays related to the projects Helicobacter Pylori vaccine and meningococcal Serogroup A, C, W-135 and Y conjugate vaccine.
In the following eight years she joined the Protein Purification group (Novartis Vaccines, Siena) as Process Development and GMP Expert: her main responsibility was antigens purification and characterization analyses related to the vaccines projects Meningococcal Serogroup B, Streptococcus Pyogenes Serogroup A and Staphylococcus Aureus. During this time she was also involved in the process Scale-up and Phase I clinical trial material production. Later she worked as Production Support Expert (four years) in the GMP documentation group (TD Production Support), taking on Training Coordinator and Change Owner positions, managing staff training and GMP changes.
Then she worked four years as Associate Scientist in the TD Analytical Development Immunoassay group (Glaxo Smith Kline Vaccines, Siena) performing In-Vitro Relative Potency assays for the Meningococcal Serogroup B vaccine. In April 2021 she joined the team led by Dr. Rino Rappuoli at the Fondazione Toscana Life Sciences (TLS, Siena) where she is working on the isolation of human monoclonal antibodies against antimicrobial-resistant pathogens and against Sars-CoV-2 virus.